U.S. markets closed

Galera Therapeutics, Inc. (GRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.18+0.18 (+1.64%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close11.00
Open11.21
Bid10.25 x 1300
Ask13.00 x 800
Day's Range10.45 - 11.39
52 Week Range5.58 - 15.00
Volume34,433
Avg. Volume72,326
Market Cap278.957M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-173.09
Earnings DateNov 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully
    Simply Wall St.

    We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Is GRTX A Good Stock To Buy Now?
    Insider Monkey

    Is GRTX A Good Stock To Buy Now?

    Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]

  • Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
    GlobeNewswire

    Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

    MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020. The pre-recorded fireside chat can be accessed beginning November 23, 2020, from the Investors page of Galera’s website, investors.galeratx.com, and will remain available for 60 days following the conference.About Galera TherapeuticsGalera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera’s second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 clinical trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.Investor Contacts: Christopher Degnan Galera Therapeutics, Inc. 610-725-1500 cdegnan@galeratx.comJennifer Porcelli Solebury Trout 646-378-2962 jporcelli@soleburytrout.comMedia Contact: Heather Anderson 6 Degrees 919-827-5539 handerson@6degreespr.com